Avid Bioservices has officially been acquired by GHO Capital Partners and Ampersand Capital Partners. The acquisition supports Avid’s next phase of growth, with a focus on service expansion, talent investment, and broader geographic reach. Avid, a biologics contract development and
Avid Bioservices, Inc., a contract development and manufacturing organization (CDMO), announced a definitive merger agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. As part of the merger
Avid Bioservices Contract Manufacturing & Development (CDMO) Profile Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
